Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

Blood
Nicolaus KrögerFrancesco Passamonti

Abstract

Allogeneic hematopoietic stem cell transplantation (SCT) is the only curative option for patients with primary myelofibrosis (PMF), but information on its net advantage over conventional therapies is lacking. Using ad hoc statistical analysis, we determined outcomes in 438 patients <65 years old at diagnosis who received allogenic SCT (n = 190) or conventional therapies (n = 248). Among patients at low risk per the Dynamic International Prognostic Scoring System (DIPSS) model, the relative risk of death after allogenic SCT vs those treated with nontransplant modalities was 5.6 (95% CI, 1.7-19; P = .0051); for intermediate-1 risk it was 1.6 (95% CI, 0.79-3.2; P = .19), for intermediate-2 risk, 0.55 (95% CI, 0.36-0.83; P = .005), and for high risk, 0.37 (95% CI, 0.21-0.66; P = .0007). Thus, patients with intermediate-2 or high-risk PMF clearly benefit from allogenic SCT. Patients at low risk should receive nontransplant therapy, whereas individual counseling is indicated for patients at intermediate-1 risk.

References

Jan 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tiziano BarbuiUNKNOWN European LeukemiaNet
Mar 2, 2012·The New England Journal of Medicine·Claire HarrisonGiovanni Barosi
Jul 6, 2014·Blood·Elisa RumiUNKNOWN Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators

❮ Previous
Next ❯

Citations

Sep 8, 2015·Expert Review of Hematology·Samah AlimamClaire Harrison
Jan 31, 2016·Current Opinion in Hematology·Francesco PassamontiMargherita Maffioli
Oct 11, 2015·American Journal of Hematology·Natasha Kekre, Vincent T Ho
Oct 23, 2015·American Journal of Hematology·Ayalew Tefferi
Dec 15, 2015·Current Hematologic Malignancy Reports·Auro ViswabandyaVikas Gupta
Dec 10, 2015·Internal Medicine Journal·P J HoD M Ross
May 18, 2016·Expert Opinion on Drug Safety·J M O'SullivanC N Harrison
Nov 25, 2016·Expert Review of Hematology·Guido Lancman, John Mascarenhas
Jul 14, 2016·Journal of Oncology Practice·Nicolaus Kröger
Apr 9, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicolaus KrögerMichael Heuser
May 14, 2017·Blood·Prithviraj Bose, Srdan Verstovsek
Feb 27, 2018·Expert Opinion on Emerging Drugs·Aditya Shreenivas, John Mascarenhas
Nov 4, 2017·Current Hematologic Malignancy Reports·Kristen Pettit, Olatoyosi Odenike
Apr 14, 2018·Blood·Francesco Passamonti, Margherita Maffioli
Sep 21, 2018·Leukemia & Lymphoma·Kamal MenghrajaniMoshe Talpaz
Feb 6, 2018·Annals of Hematology·Juan-Carlos Hernández-BoludaFrancisco Cervantes
Jul 16, 2019·European Journal of Haematology·Giulia DaghiaNicolaus Kröger
Jun 2, 2016·American Society of Clinical Oncology Educational Book·Ruben A Mesa, Francesco Passamonti
Dec 12, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paola GuglielmelliAyalew Tefferi
Sep 13, 2019·Blood Cancer Journal·Michael SchieberBrady Stein
Aug 24, 2017·Current Opinion in Hematology·Noa LaviTsila Zuckerman
Feb 23, 2020·Expert Review of Hematology·Lara MannelliAlessandro M Vannucchi
Sep 5, 2019·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Yevgeniy A LinnikDeborah L Ornstein
Oct 23, 2019·International Journal of Hematology·Orly LeivaKatya Ravid
Aug 20, 2015·Current Hematologic Malignancy Reports·Nicolaus Kröger
Dec 20, 2017·HemaSphere·Leonard Naymagon, John Mascarenhas
Feb 29, 2020·Therapeutic Advances in Hematology·Lining ZhangSizhou Feng
May 10, 2020·Blood Advances·Krisstina GowinWael Saber
Dec 4, 2016·Hematology·Rebecca Devlin, Vikas Gupta
Sep 14, 2018·Therapeutic Advances in Hematology·Michael ByrneMichael R Savona
May 18, 2019·Blood·Francesco Passamonti
Jul 2, 2020·Cells·Lukas M Braun, Robert Zeiser
Dec 4, 2016·Hematology·Francesco Passamonti, Margherita Maffioli
Aug 10, 2017·Drugs·Douglas TremblayJohn Mascarenhas
May 2, 2018·Current Hematologic Malignancy Reports·Francesco PassamontiMargherita Maffioli
Mar 22, 2020·Annals of Hematology·Claire N HarrisonRuben A Mesa
Apr 14, 2018·Nature Communications·Margaux SevinAurélie de Thonel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.